CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
2.06%Below 5Y avg (3.03%)
Annual Rate
CNY 0.30Paid annual
Payout Ratio
85.7%High
Payback Period
47.6 yr
Last Ex-Dividend
May 29, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.33BCNY345.52M · vs all stocks (USD)
Trailing P/E
41.54xRevenue (TTM)
260.58MCNY38.70M · vs all stocks (USD)
Profit Margin
21.50%Beta
0.3040xvs all stocks
52-Week Change
-15.27%vs all stocks
Market Capitalization
2.33BCNY345.52M · vs all stocks (USD)
Enterprise Value
1.55BCNY230.93M · vs all stocks (USD)
Trailing P/E
41.54xPrice to Sales (TTM)
8.93xPrice to Book (MRQ)
2.69xEnterprise to Revenue
5.97xEnterprise to EBITDA
22.03xGross Margin
45.37%Profit Margin
21.50%Operating Margin
32.09%Return on Assets (TTM)
3.79%Return on Equity (TTM)
6.52%Revenue (TTM)
260.58MCNY38.70M · vs all stocks (USD)
Revenue per Share (TTM)
1.63CNYUpdated Aug 19, 2026Quarterly Revenue Growth
-5.10%Gross Profit (TTM)
108.04MCNY16.05M · vs all stocks (USD)
EBITDA (TTM)
61.04MCNY9.07M · vs all stocks (USD)
Net Income (TTM)
56.04MCNY8.32M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
7.40%Operating Cash Flow (TTM)
78.90MCNY11.72M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
60.63MCNY9.01M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.3000CNYUpdated Aug 19, 2026Trailing Annual Dividend Yield
2.06%vs all stocks
5-Year Average Dividend Yield
3.03%vs all stocks
Payout Ratio
85.71%Revenue
265.36MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
162.50MCNYFY2025 · Dec 31, 2025Gross Profit
102.86MCNYFY2025 · Dec 31, 2025Operating Income
48.36MCNY7.18M · vs all stocks (USD)
Pre-tax Income
63.43MCNYFY2025 · Dec 31, 2025Income Tax Expense
9.22MCNYFY2025 · Dec 31, 2025Net Income
54.21MCNYFY2025 · Dec 31, 2025EBIT
48.36MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
63.33MCNYFY2025 · Dec 31, 2025Research & Development
13.35MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
16.73MCNYFY2025 · Dec 31, 2025Other Operating Expenses
5.30MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
11.13MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.3400CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.3400CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
159.45MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
159.45MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
54.21MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
84.98MCNYFY2025 · Dec 31, 2025Free Cash Flow
81.54MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
311.84MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
54.21MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
4.93MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
25.84MCNYFY2025 · Dec 31, 2025Capital Expenditures
-3.45MCNYFY2025 · Dec 31, 2025Sale of Investments
5.94MCNYFY2025 · Dec 31, 2025Other Investing Activity
-215.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-212.50MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-48.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-48.00MCNYFY2025 · Dec 31, 2025Shares Outstanding
160.00MSharesUpdated Aug 19, 2026Float Shares
78.00MSharesUpdated Aug 19, 2026% Held by Insiders
53.46%vs all stocks
% Held by Institutions
2.11%vs all stocks
Total Cash (MRQ)
771.53MCNY114.59M · vs all stocks (USD)
Total Cash per Share (MRQ)
4.82CNYUpdated Aug 19, 2026Total Debt (MRQ)
0.00CNYvs all stocks (USD)
Total Debt to Equity (MRQ)
0.00xCurrent Ratio (MRQ)
16.38xBook Value per Share (MRQ)
5.40CNYUpdated Aug 19, 2026Total Assets
889.42MCNY132.10M · vs all stocks (USD)
Total Current Assets
767.34MCNYFY2025 · Dec 31, 2025Total Liabilities
52.60MCNYFY2025 · Dec 31, 2025Total Non-current Assets
122.08MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
7.90MCNYFY2025 · Dec 31, 2025Total Current Liabilities
44.71MCNYFY2025 · Dec 31, 2025Cash
310.25MCNYFY2025 · Dec 31, 2025Cash Equivalents
1.58MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
311.84MCNYFY2025 · Dec 31, 2025Other Short-term Investments
400.00MCNYFY2025 · Dec 31, 2025Accounts Receivable
10.42MCNYFY2025 · Dec 31, 2025Inventory
43.27MCNYFY2025 · Dec 31, 2025Accounts Payable
28.58MCNYFY2025 · Dec 31, 2025Other Current Liabilities
107.31KCNYFY2025 · Dec 31, 2025Common Stock (Book)
160.00MCNYFY2025 · Dec 31, 2025Retained Earnings
389.84MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
836.81MCNY124.28M · vs all stocks (USD)
52-Week Low
11.53CNYUpdated Aug 19, 202652-Week High
18.25CNYUpdated Aug 19, 202652-Week Change
-15.27%vs all stocks
Beta
0.3040xvs all stocks
50-Day MA
13.22CNYUpdated Aug 19, 2026200-Day MA
15.13CNYUpdated Aug 19, 2026Avg 10-Day Volume
6.30MSharesUpdated Aug 19, 2026Avg 30-Day Volume
7.50MSharesUpdated Aug 19, 2026Diluted EPS (TTM)
0.3500CNYUpdated Aug 19, 20261 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow is this stock valued?
Close Below 40W SMA With Profitability
The price sits below its 40-week average, on three profitable years and cash above profit.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Cellectis S.A.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Palisade Bio Inc.
Tier 1ProductionApproval-Gated PipelineRule
Deva Holding A.S.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Perspective Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Standard Biotools Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hainan Huluwa Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Zhenyuan Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Bionote Inc.
Tier 1ProductionApproval-Gated PipelineRule
Suzhou Fushilai Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Anbio Biotechnology Limited
1 interpretationClose Below 40W SMA With Profitability
Shanghai Mechanical and Electrical Industry Co., Ltd.
1 interpretationClose Below 40W SMA With Profitability
Jiajiayue Group Co., Ltd.
1 interpretationClose Below 40W SMA With Profitability